Navigation Links
Ventana Receives FDA Clearance for p53 (DO-7) Image Analysis and Digital Read Applications
Date:5/7/2012

TUCSON, Ariz., May 7, 2012 /PRNewswire/ -- Ventana Medical Systems, Inc. (Ventana), a member of the Roche Group, received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the VENTANA Companion Algorithm p53 (DO-7) image analysis application using the VENTANA iScan Coreo Au scanner and VIRTUOSO software.  Currently, Ventana is the only company offering an FDA-cleared p53 image analysis algorithm for determining p53 expression levels in breast cancer patients.  Ventana is offering the p53 (DO-7) image analysis algorithm in addition to the company's FDA-cleared algorithms for HER2 (4B5), PR (1E2), and Ki-67 (30-9).

"As a market leader and long-term innovator in anatomic pathology, Ventana is committed to improving the lives of cancer patients," says Mara G. Aspinall, President, Ventana Medical Systems, Inc.  "We provide the most clinically-validated, FDA-cleared digital pathology algorithms in the market today.  When you combine this with our broad portfolio of instruments and assays, and our expertise in laboratory knowledge management and workflow, it is clear that Ventana is positioned to deliver the most comprehensive digital pathology solutions available globally."

The p53 (DO-7) image analysis algorithm assists pathologists in the detection and semi-quantitative measurement of p53 (DO-7) protein in formalin-fixed, paraffin-embedded normal and neoplastic tissue.  When the p53 (DO-7) algorithm is used in conjunction with the CONFIRM anti-p53 (DO-7) Primary Antibody, it may be used as an aid in the assessment of p53 expression in breast cancer patients (but is not the sole basis for treatment).  The FDA clearance includes all of the components of the VENTANA laboratory workflow solution when used as a system, including the company's BenchMark XT slide stainer, p53 clone DO-7, iView and ultraView DAB detection systems, VENTANA iScan Coreo Au slide scanner, and Virtuoso image management software.

Steve Burnell, PhD, VP, Ventana Digital Pathology and Workflow states, "As is the case for Ki-67, Ventana is the only company offering a 510(k)-cleared algorithm for p53 today. Our increasing Companion Algorithm portfolio of FDA-cleared products is evidence both of our unique capabilities in this field as well as our commitment to empower our customers to deliver the highest standards of patient care through the most robust digital pathology solutions available."

In conjunction with this clearance, Ventana also received FDA clearance for the digital read application that allows pathologists to interpret p53 (DO-7) stained slides as images on a computer monitor using the iScan Coreo Au scanner with VIRTUOSO software.

About Ventana Medical Systems, Inc.

Ventana Medical Systems, Inc. ("VMSI") (SIX: RO, ROG; OTCQX: RHHBY), a member of the Roche Group, innovates and manufactures instruments and reagents that automate tissue processing and slide staining for cancer diagnostics. VENTANA solutions are used in clinical histology and drug development research laboratories worldwide. The company's intuitive, integrated staining, workflow management platforms, and digital pathology solutions optimize laboratory efficiencies to reduce errors, support diagnosis and inform treatment decisions for anatomic pathology professionals. Together with Roche, VMSI is driving Personalized Healthcare through accelerated drug discovery and the development of "companion diagnostics" to identify the patients most likely to respond favorably to specific therapies. Visit www.ventana.com to learn more.

VENTANA, the VENTANA logo,  iScan, BenchMark and VIRTUOSO are trademarks of Roche.

VMSIMedia Relations

Jacqueline Bucher
Director, Corporate Communications
Phone: 520-877-7288
e-mail: jacquie.bucher@ventana.roche.com


'/>"/>
SOURCE Ventana Medical Systems, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Ventana Introduces the BenchMark Special Stains Platform
2. Ventana Receives FDA Clearance for Ki-67 (30-9) Image Analysis and Digital Read Applications
3. Ventana Medical Systems, Inc. to Collaborate with Bayer on Companion Diagnostic Test for New Biological Cancer Therapy
4. Syndax Pharmaceuticals Signs Agreement with Ventana Medical Systems, Inc. to Develop Companion Diagnostic Test for Entinostat
5. Ventana Medical Systems, Inc. and Advanced Cell Diagnostics Enter Worldwide Co-Promotion Agreement for Fully Automated RNA In Situ Hybridization Assay Systems
6. Ventana Medical Systems, Inc. Introduces Groundbreaking Laboratory Workflow Integration
7. Ventana Medical Systems, Inc. Unveils High-throughput Slide Scanner for Digital Pathology
8. Ventana Medical Systems, Inc. Receives FDA Approval for the First Fully Automated Diagnostic Assay for HER2 Gene Status Determination in Breast Cancer Patients
9. Ventana Medical Systems, Inc. Launches Virtuoso Software for Digital Pathology
10. CareGiver, Ventana Medical Systems, Inc. Remote Instrument Support, Has Expanded to Include the Ventana BenchMark ULTRA Automated Stainer
11. Endologix Announces First Clinical Implant of Ventana™ Stent Graft
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/15/2017)... 2017   Mostyn Law and Gulf Coast Regional Blood ... . The Mostyn Law family has had 3 ... is why Mostyn Law is partnering with Gulf Coast ... its appreciation. Blood supplies are running low. Gulf Coast ... hospital needs in August. That is why the blood center reached ...
(Date:8/15/2017)... , Aug. 15, 2017  AOTI Inc. announced today that ... Therapy Inc., has recently opened a New York City Office in ... usage of its unique Topical Wound Oxygen (TWO 2 ) homecare ... the Accreditation Commission for Health Care (ACHC) under the company,s DMEPOS ... ...
(Date:8/8/2017)... -- BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical company focused ... for the second quarter ended June 30, 2017. ... and to date: ... Company,s lead project, BL-8040: Announced plans ... novel stem cell mobilization treatment for autologous bone-marrow transplantation ...
Breaking Medicine Technology:
(Date:8/24/2017)... ... August 24, 2017 , ... Lori ... the development and advances in Desensitization therapy to improve the outcomes of organ ... about his remarkable journey of his 25 years of research in developing therapies ...
(Date:8/24/2017)... ... August 24, 2017 , ... Prime candidates for home ... have a condition that needs further monitoring such as surgery, stroke, heart attack ... stable, such as diabetes, high blood pressure, heart/lung disease, arthritis and stroke. ...
(Date:8/23/2017)... ... 2017 , ... The Arc Mercer, Capitol County’s premier provider of programs and ... community organization for people with special needs. The group, the Special Needs Alliance for ... of New Jersey – but the first in the entire country! , SNAP was ...
(Date:8/23/2017)... ... 2017 , ... Drs. Steven White and Brad Haines are pleased to announce ... of this offer, valued at more than $300 per year, new patients can enjoy ... patients receive a complimentary professional whitening procedure. , Stained or yellowed tooth enamel ...
(Date:8/23/2017)... ... ... Awards have announced the winners of the Best of the IBA Awards in The 2017 ... in the 2017 IBAs were not able to apply for the Best of the IBA ... awards won in the IBAs with a Gold Stevie win counting for three points, a ...
Breaking Medicine News(10 mins):